Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | CCR9 | P51686 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSPO | P30536 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4311962 | 0.93 | MAPT (0.41) | MAPTCCR9MTNR1AMTNR1BTP53 | |
| SCHEMBL4317662 | 0.90 | CCR9 (0.40) | MAPTCCR9MTNR1AMTNR1BTP53 | |
| SCHEMBL4311380 | 0.89 | MAPT (0.47) | MAPTLMNATP53THRB | |
| SCHEMBL4309693 | 0.89 | MAPT (0.42) | MAPTCCR9LMNAMTNR1AMTNR1B | |
| SCHEMBL4315035 | 0.89 | CCR9 (0.39) | MAPTCCR9MTNR1AMTNR1BTP53 | |
| SCHEMBL4311475 | 0.89 | CCR9 (0.39) | MAPTCCR9MTNR1AMTNR1BTSPO | |
| SCHEMBL4323857 | 0.89 | MAPT (0.39) | MAPTCCR9LMNAMTNR1AMTNR1B | |
| SCHEMBL4316432 | 0.88 | MAPT (0.41) | MAPTCCR9LMNAMTNR1AMTNR1B | |
| SCHEMBL4312933 | 0.88 | MAPT (0.40) | MAPTCCR9LMNAMTNR1AMTNR1B | |
| SCHEMBL4310998 | 0.86 | MAPT (0.48) | MAPTCCR9TP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | claimed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | MAPT 498/4885CCR9 4698/4885LMNA 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.